Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why

Neurocrine will acquire SLNO for $2.9B in cash at $53 per share, prompting a surge in SLNO shares on the announcement. The acquisition brings Vykat XR into Neurocrine and expands its rare disease and endocrinology portfolio, a strategic M&A move with material implications for both companies' product pipelines.

Analysis

Neurocrine will acquire SLNO for $2.9B in cash at $53 per share, prompting a surge in SLNO shares on the announcement. The acquisition brings Vykat XR into Neurocrine and expands its rare disease and endocrinology portfolio, a strategic M&A move with material implications for both companies' product pipelines.